Observational studyAdvances in therapy2016

Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis.

Grant W Cannon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.